Emanuela Palmerini - Concepedia

Author

Emanuela Palmerini

Also Known As

E Palmerini, E. Palmerini, Emanuela Palmerini, John H. Healey, Marie-Cécile le Deley, Michele Baccarani, Palmerini E, Palmerini, Emanuela, Richard A Brand, T Frisoni

329

Publications

11.7K

Citations

H-Index

Concepts

All Affiliations

Istituto Ortopedico Rizzoli Fondazione IRCCS Istituto Nazionale dei Tumori Istituti di Ricovero e Cura a Carattere Scientifico Candiolo Cancer Institute Leiden University Medical Center

About

Emanuela Palmerini is an author at Istituto Ortopedico Rizzoli specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	41	5.4K
2	Health Sciences	5	5	133
3	Cell Biology	1	1	12
4	Diagnostic Sciences	1	1	11
5	Gastroenterology	1	1	509

Emanuela Palmerini

112

Publications

9.4K

Citations

H-Index

Page 1

	Year	Citations
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ Alessandro Gronchi, Aisha Miah, Angelo Paolo Dei Tos, Annals of Oncology Surgical OncologySoft Tissue SurgeryVisceral SarcomasSurgical PathologyHistopathology	2021	879
Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up Paolo G. Casali, Jean‐Yves Blay, N. Abecassis, Annals of Oncology Surgical OncologyGastrointestinal OncologyMedicineSurgical PathologyGastroenterology	2021	509
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial Alessandro Gronchi, Stefano Ferrari, Vittorio Quagliuolo, The Lancet Oncology Tumor BiologySurgical OncologyMalignant DiseaseMedicineStandard Chemotherapy	2017	473
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial William D. Tap, Hans Gelderblom, Emanuela Palmerini, The Lancet Surgical OncologyOncologyMedicineRandomised Phase 3Pathology	2019	454
Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up Sandra J. Strauss, Anna Maria Frezza, N. Abecassis, Annals of Oncology Bone DiseaseBone SarcomasSurgical OncologyBone ImagingMedicine	2021	408
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study Giovanni Grignani, Emanuela Palmerini, Palma Dileo, Annals of Oncology Surgical OncologyPhase Ii TrialMedicineUnresectable High-grade OsteosarcomaMetronomic Therapy	2011	353
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial Giovanni Grignani, Emanuela Palmerini, Virginia Ferraresi, The Lancet Oncology Surgical OncologyMedicineStandard TreatmentNon-randomised Phase 2Cancer Treatment	2014	328
Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study James Glasbey, Adesoji Ademuyiwa, Adewale Adisa, The Lancet Oncology	2021	280
Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups Alessandro Gronchi, Emanuela Palmerini, Vittorio Quagliuolo, Journal of Clinical Oncology	2020	245
Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study Sant P. Chawla, Jean‐Yves Blay, Piotr Rutkowski, The Lancet Oncology Bone DiseaseMedicinePathologyOsteoporosisGiant-cell Tumour	2019	244

Page 1